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In animal models, the incretin hormone GLP-1 affects Alzheimer’s disease (AD).
We hypothesized that treatment with GLP-1 or an analog of GLP-1 would prevent
accumulation of Aβ and raise, or prevent decline of, glucose metabolism (CMRglc) in
AD. In this 26-week trial, we randomized 38 patients with AD to treatment with the GLP-
1 analog liraglutide (n = 18), or placebo (n = 20). We measured Aβ load in brain with
tracer [11C]PIB (PIB), CMRglc with [18F]FDG (FDG), and cognition with the WMS-IV scale
(ClinicalTrials.gov NCT01469351). The PIB binding increased significantly in temporal
lobe in placebo and treatment patients (both P = 0.04), and in occipital lobe in treatment
patients (P = 0.04). Regional and global increases of PIB retention did not differ between
the groups (P ≥ 0.38). In placebo treated patients CMRglc declined in all regions,
significantly so by the following means in precuneus (P = 0.009, 3.2 µmol/hg/min,
95% CI: 5.45; 0.92), and in parietal (P = 0.04, 2.1 µmol/hg/min, 95% CI: 4.21;
0.081), temporal (P = 0.046, 1.54 µmol/hg/min, 95% CI: 3.05; 0.030), and occipital
(P = 0.009, 2.10 µmol/hg/min, 95% CI: 3.61; 0.59) lobes, and in cerebellum (P = 0.04,
1.54 µmol/hg/min, 95% CI: 3.01; 0.064). In contrast, the GLP-1 analog treatment
caused a numerical but insignificant increase of CMRglc after 6 months. Cognitive scores
did not change. We conclude that the GLP-1 analog treatment prevented the decline of
CMRglc that signifies cognitive impairment, synaptic dysfunction, and disease evolution.
We draw no firm conclusions from the Aβ load or cognition measures, for which the
study was underpowered.
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INTRODUCTION
Type 2 diabetes (T2D) raises the risk of Alzheimer’s disease
(AD) (Xu et al., 2009). Suggested common pathophysiological
mechanisms include deficient insulin and glucagon-like
peptide-1 (GLP-1) signaling (Femminella and Edison, 2014).
GLP-1 stimulates β-cell neogenesis, growth, and differentiation,
and inhibits β-cell apoptosis (Nauck, 2004). In the pancreas,
β-cells secrete amylin that shares characteristics with Aβ. In
animal models of T2D, β-cells accumulate amyloid, and GLP-
1 treatment of the model animals relieves amyloid toxicity
(Ahren et al., 2007). Cells of hypothalamus and hippocampus
abundantly express GLP-1 receptors and GLP-1 induces neurite
outgrowth (Perry and Greig, 2005). GLP-1 protects against
excitotoxic cell death and against the toxic effects of Aβ1−42
by binding to receptors expressed in soma and dendrites of
large neurons (Perry and Greig, 2005). In mice, intraventricular
administration of GLP-1 reduces nerve cell damage triggered
by neurotoxic stimuli, and GLP-1 receptor activation improves
learning and memory (During et al., 2003). Treatment of mice
with the GLP-1 analog liraglutide in an AD model halted the
progression of decline in memory function (Hansen et al.,
2015).
Current AD treatments remain symptomatic, however. GLP-1
receptor agonism potentially reverses both early and late
events in neurodegeneration (McClean et al., 2011, 2015;
McClean and Holscher, 2014). In a 1-year study of deep
brain stimulation of patients with AD, a persistent increase
of cerebral glucose metabolism was associated with improved
clinical outcome and cortical circuitry compared to a 1-
year course of pharmacotherapy (Smith et al., 2012). In
humans, GLP-1 alters brain glucose transport and metabolism
(Lerche et al., 2008; Gejl et al., 2012, 2013). Liraglutide is
a GLP-1 receptor agonist used in T2D and chronic weight
management. The analog crosses the blood–brain barrier into
brain where it raises synaptic plasticity (McClean et al.,
2010; Hunter and Holscher, 2012). GLP-1 mimetics are
reported to be neuroprotective in a range of neurodegenerative
disorders (Holscher, 2014). In the transgenic APP/PS1 mouse
model of AD, liraglutide stimulates neuronal proliferation,
improves learning, reduces plaque formation, and Aβ synthesis,
inhibits inflammation, and raises neurogenesis (McClean et al.,
2011).
In this first-in-human study, on the basis of the results
of GLP-1 analog treatment and the effects on brain glucose
metabolism, we examined the effects of liraglutide on three
vital signs in AD, cerebral glucose consumption, fibrillary
Aβ deposition, and cognition. We tested the hypothesis that
treatment with liraglutide prevents or reduces the decline of
cerebral glucose consumption measured with PET of [18F]fluoro-
2-deoxyglucose ([18F]FDG) metabolism. We also tested whether
6 months’ treatment with liraglutide would reduce the Aβ
deposition in brain of patients with AD, determined by PET of
carbon-11 labeled Pittsburgh Compound B ([11C]PIB) retention.
In parallel, we determined commensurate changes of relevant
cognitive scores.
MATERIALS AND METHODS
Study Design and Participants
We completed a 26-week, randomized, placebo-controlled,
double-blinded intervention with liraglutide (VICTOZA R©) or
placebo in patients with AD. Patients were recruited from
dementia clinics in Central Denmark, with key inclusion
and exclusion criteria listed in Table 1. Patients willing to
participate gave written informed consent. Safety data were
monitored independently throughout the study period. The
study was conducted according to the principles of the Helsinki
Declaration. The Central Denmark Regional Committees on
Biomedical Research Ethics, the Danish Data Protection Agency,
and the Danish Medicines Agency approved the protocol,
(Egefjord et al., 2012) with trial registration at ClinicalTrials.gov:
NCT01469351.
Randomization and Masking
Participants were randomly assigned (1:1) by block
randomization using block size of eight by The Hospital
Pharmacy, Central Denmark Region, Aarhus, Denmark.
Study drugs were given in coded drug packages. Investigators
and coordinators used a centralized code system for study
package administration. Investigators dispensed study drug
or matching placebo in pre-filled identically appearing pens.
Participants, carers and study staff were masked to treatment
assignment. Liraglutide or placebo was administered as “add
on” to the patients’ usual medications, including already
initiated and stabilized treatment with cholinesterase-inhibitors
for AD.
TABLE 1 | Key inclusion and exclusion criteria.
Key inclusion criteria
Adult competent persons.
Diagnosed with Alzheimer’s disease (AD) with an MMSE score of 18–21.
The diagnosis should be entirely based on clinical findings, while diagnosis by
MMSE with a score >22 should be diagnosed by spinal puncture.
Age >50 years and <80 years.
Caucasians.
Key exclusion criteria
Diabetes mellitus.
Clinically significant liver or renal impairment (serum alanine amino transferase >2
times upper reference or creatinine-clearance <60 ml/min, assessed on
Cockcroft-Gault normogram).
Clinically significant anemia.
Current or former presence of one of the following diseases with clinical relevance:
another central nervous system illness other than diagnosed depression treated
with SSRI or SSRI similar drugs; liver disease; kidney disease; endocrinological
disease other than well- controlled hypothyroidism.
Current or history of chronic or acute pancreatitis.
Patients treated with tricyclic antidepressants or neuroleptics.
Significant abnormalities in the brain detected by magnetic resonance imaging.
MMSE, Mini-Mental State Examination; SSRI, selective serotonin re-uptake
inhibitors.
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Procedures
Participants attended a screening visit to assess eligibility
followed by randomization to either liraglutide or placebo for
26 weeks. Liraglutide was administered as 0.6 mg subcutaneously
daily for 1 week; hereafter 1.2 mg daily for 1 week before
finally increasing to 1.8 mg daily. Placebo was saline in similar
volumes.
Positron Emission Tomography
The subjects underwent PET with [11C]PIB and [18F]FDG. We
synthesized [11C]PIB as previously described (Solbach et al.,
2005). PET with [11C]PIB followed previous [11C]PIB studies of
brain (Leinonen et al., 2008), apart from abbreviated recording
time. Also PET with [18F]FDG followed previous dynamic
[18F]FDG studies of brain metabolism (Lerche et al., 2008).
Heads were stabilized on a mouldable pillow. Images were
reconstructed with Ordered Subset Expectation Maximation
with point spread function (3D-OSEM-PSF) modeling using 10
iterations.
Tomography Procedures
We recorded all emission as 2D acquisitions. We completed the
first tomography with [11C]PIB, 385 MBq (range 177–435 MBq),
given intravenously as a 60-s 10 mL bolus dissolved in saline.
We initiated the second tomography with injection of 207 MBq
[18F]FDG (range 167–218 MBq) as a 30-s 5 mL bolus, also
dissolved in saline.
Magnetic Resonance Imaging
We acquired anatomical images for co-registration with the
3T Magnetom Tim Trio system (Siemens Healthcare, Erlangen,
Germany) with 3D T1-weighted high-resolution anatomic scan
of magnetization-prepared rapid acquisition gradient echo
(MPRAGE) sequence.
Motion Correction and Co-registration
We co-registered PET images with individual MR images
to an MR template, and evaluated the quality of each co-
registration by visual inspection in three planes. PET-to-
MR correlated images were transformed into a common
stereotaxic coordinate space (Talairach and Tournoux, 1988), and
anatomical volumes of interest were used to extract time-activity-
curves (TACs) from the dynamic PET images for the FDG and
PIB analyses.
Outcomes
The primary outcome was Aβ deposition as determined by
[11C]PIB PET. Secondary outcome was the glucose metabolic rate
measured with [18F]FDG. We also tested changes in cognitive
capability.
Kinetic Analysis of [11C]PIB Retention
We used the flow-independent Washout Allometric Reference
Method (WARM) for analysis of washout and binding of
[11C]PIB expressed as the tracer’s binding potential in brain
(BPND) (Rodell et al., 2013). We directly calculated the BPND
without linearization with the operational equation,
BPND(T) =
m∗
T∫
0
ln
[
m∗ND(t)
m∗ND(0)
]
dt
m∗ND
T∫
0
ln
[
m∗(t)
m∗(0)
]
dt
− 1
where m∗ and m∗ND are measured PET signals as time-activity
curves in regions with displaceable binding, and in a reference
region, respectively. In this equation, the binding potential is
corrected for flow differences, according to the initially deposited
tracer, and the exponential nature of the washout.
Cerebral Blood Flow
We used the rapid initial clearance of tracer PIB to obtain a
surrogate absolute measure of cerebral blood flow (sCBF) (Rodell
et al., 2013).
Kinetic Analysis of [18F]FDG Uptake
Regional tissue time–activity curves for [18F]FDG uptake were
extracted for eight predefined Regions-of-Interest (ROI). We
calculated the net influx rate of [18F]FDG (K) from arterial
blood samples and dynamic PET images applying multiple-times
graphical analysis according to Gjedde (1982) and Patlak et al.
(1983) for irreversible tracer uptake, with simple non-iterative
perpendicular line fitting. Here, CMRglc = K∗ Ca/LC, where
Ca is the arterial steady-state plasma glucose concentration, and
LC is a common lumped constant value of 0.76, shown not to
vary among the groups by calculation from kinetic parameters
(Kuwabara et al., 1990).
Regions-of-Interest (ROI)
In the analysis of [11C]PIB-PET, we included eight predefined
areas of interest, the cingulate cortex, precuneus, frontal, parietal,
temporal, and occipital lobes, and cerebellum and cerebral cortex.
The cerebellar cortex was chosen as reference for the [11C]PIB
retention measures obtained from parametric PET image maps
by standard model based segmentation. For the analysis of the
uptake of [18F]FDG, we included the same eight predefined
areas in the analyses, to ensure that analyses covered the
entire brain and that possible anatomical differences would be
detected.
Cognitive Testing
We evaluated cognition by the “Brief cognitive examination”
from the Wechsler Memory Scale (WMS-IV) (Scheltens et al.,
2010), the test examining orientation, time estimation, mental
control, clock drawing, incidental recall, inhibition, and verbal
reproduction.
Statistical Analysis
The treatment period was set to 6 months, the period after
which most clinical effects with liraglutide are achieved. The
power calculation was based on a risk of type 1 error of 0.05
and risk of type 2 error of 0.20. We predicted differences
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of cerebral glucose consumption of 15% (Lerche et al., 2008)
and changes of amyloid load of 15% (Leinonen et al., 2008)
with SD set to 15%. The numbers yielded a sample size of
n = 2 (1.96–0.84)2 ∗ 0.152/0.152 = 16. We analyzed treatment
group data blindly by two-sample, Student’s two independent
samples t-test to determine the significance of group differences,
and by Student’s paired t-tests to determine changes within
groups. P-values < 0.05 were considered indicative of significant
difference.
RESULTS
We randomly assigned 38 patients with AD to receive either
the GLP-1 analog liraglutide (n = 18) or placebo (n = 20).
Fourteen patients in the liraglutide group and all patients in
the placebo group completed the study. In the liraglutide group,
13 patients had PET with [11C]PIB, and 14 patients had PET
with [18F]FDG, before and after treatment, compared to 19
with [11C]PIB, and 19 patients with [18F]FDG in the placebo
group. All completed the cognitive examination. Tomography
sessions were incomplete in two patients for CMRglc and one
patient for PIB binding, leaving 18 patients from the placebo
group and 13 patients from the liraglutide group in the final
analysis of [11C]PIB retention, and 17 patients from the placebo
group and 14 patients from the liraglutide group in the final
analysis of [18F]FDG uptake. Of the non-completers, one subject
was excluded for drug-related reasons (nausea and anorexia
after liraglutide for 35 days), and the rest for non-drug-related
reasons that included; death of husband, one was diagnosed
with cancer of the bladder which was evaluated by the principal
investigator as being independent of the study drug treatment.
One subject wanted to stop participation before randomization
and one subject experienced nausea, vomiting, and fever after
administration of 1 dose (0.6 mg) of the study drug which was
evaluated by the principal investigator as being independent of
the study drug treatment. All drop-outs had been treated with
liraglutide.
Demographic and Clinical
Characteristics
Disease duration was longer in the liraglutide group (30 vs.
15 months, P = 0.015). Including dropouts in the analysis, the
pattern remained significant (28 vs. 15 months, P= 0.018). There
were no other significant differences at baseline (Tables 2 and 3).
The liraglutide group was slightly younger (63.1 vs. 66.6 years,
P= 0.16; or 65.4 vs. 66.6 years, P= 0.61 including drop-outs) and
the female/male ratio was skewed. Table 2 lists the demographic
characteristics at completion.
We found a significant difference in fasting plasma glucose
between the two groups (5.6 mM in the placebo group and
5.1 mM in the GLP-1 analog group, P = 0.0041) after 6 months;
HbA1c remained unchanged. Weight decreased in the liraglutide
group during the first 3 months, hereafter weight curves were
parallel (weight loss at 6 months: 4.9 kg vs. 1.6 kg, P < 0.01). We
observed a significant reduction in systolic and diastolic blood
pressure in the liraglutide group at the end of the study period
TABLE 2 | Demographic and baseline characteristics for completers at
randomisation.
Placebo group Liraglutide group P
mean (range; SEM) mean (range; SEM)
n 20 14
Age, y 66.6 (50–80; 1.8) 63.1 (55–70; 1.3) 0.16
Sex 15Male/5Female 6 Male/8 Female
Gender (% female) 25 57 −
Wechsler Memory
Scale
27.2 (0–57; 3.8) 27.1 (5–44; 3.4) 0.99
Duration of Alzheimer’s
disease (AD), months
15 (1–41; 2.5) 29.5 (5–70; 5.8) 0.015∗
Onset, years 65.3 (49–77; 1.9) 60.3 (50–67; 1.4) 0.054
Data are presented as mean range and standard error of the mean (SEM),
and p-values were calculated using unpaired t-test. The Wechsler Memory
Scale (WMS-IV) score provides a single score of overall cognitive performance;
∗P < 0.05.
(P = 0.015 and P = 0.035, respectively.) We found no significant
difference in heart rate between the two groups at the end of the
study (P = 0.67). Patient characteristics at baseline and 6 months
are listed in Table 3.
Parametric PET Measures
[11C]PIB Retention (Figure 1)
Percentage changes of ligand binding potential in brain (BPND)
between the baseline and the 6-month follow-up are shown in
Figure 1A. [11C]PIB binding (Figure 1B) increased significantly
by the folllowing mean ratio(s) in temporal lobe (P = 0.04,
0.036, 95% CI: 0.0012; 0.070), and numerically but insignificantly
in occipital lobe (P = 0.09, 0.023, 95% CI: −0.0043; 0.050), in
the placebo group brains. In liraglutide group brains, [11C]PIB
binding increased significantly by the following mean ratios in
the temporal (P= 0.04, 0.056, 95% CI: 0.0017; 0.11) and occipital
(P = 0.04, 0.048, 95% CI: 0.0013; 0.094) lobes. Also in the GLP-
1 analog treatment group, we found numerical but insignificant
increases by the following mean ratios in the cingulate (P = 0.09,
0.088, 95% CI: −0.017; 0.19) and cerebral (P = 0.09, 0.055, 95%
CI: −0.0099; 0.12) cortices, and a numerical but insignificant
mean ratio decrease in cerebellum (P = 0.09, 0.010, 95% CI:
0.023;−0.0019). The ratios of the mean post-treatment [11C]PIB
retentions to the pre-treatment baseline in eight ROIs are shown
in Figure 1B. The average session 2/session 1 ratios were not
significantly different between the groups (P ≥ 0.38) in any
region.
Using the rapid initial clearance of [11C]PIB as a surrogate
absolute measure of sCBF, we found that sCBF increased in the
placebo group but not in the liraglutide group. In the placebo
group, sCBF increased significantly by the following means in the
frontal (P = 0.04, 3.56 ml/hg/min, 95% CI: 0.17; 6.94), parietal
(P = 0.04, 3.27 ml/hg/min, 95% CI: 0.10; 6.45), and occipital
(P = 0.02, 3.27 ml/hg/min, 95% CI: 0.10; 6.45) lobes, and in
cerebellum (P = 0.009, 4.47 ml/hg/min, 95% CI: 1.28; 7.65), and
in cortex as a whole (P = 0.03, 3.61 ml/hg/min, 95% CI: 0.41;
6.81). Numerical but insignificant mean increases were noted in
cingulate cortex (P= 0.08, 3.40 ml/hg/min, 95% CI:−0.48; 7.28),
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TABLE 3 | Patient characteristics.
Baseline Placebo group (n = 20) Liraglutide group (n = 14) Placebo vs. liraglutide group
mean (SEM) mean (SEM) P
Fasting plasma-glucose (mmol/L) 5.8 (0.2) 5.6 (0.2) 0.24
Glycated hemoglobin (HbAlc) 0.056 (0.001) 0.055 (0.0006) 0.41
Plasma-cholesterol total(mmol/L) 5.9 (0.3) 5.7 (0.2) 0.67
Weight (kg) 77.8 (3.0) 74.1 (2.1) 0.38
Body Mass Index (BMI) (kg/m 25.1 (0.7) 25.1 (1.0) 0.96
Systolic blood pressure (mmHg) 149.7 (4.3) 144.1 (6.3) 0.46
Diastolic blood pressure (mmHg) 87.5 (2.4) 83.9 (2.5) 0.32
Heart rate (bpm) 62.7 (3.2) 64.8 (2.8) 0.64
After 6 Months Placebo group (n = 20) Liraglutide group (n = 14) Placebo vs. liraglutide group Change placebo vs.
change liraglutide group
mean (SEM) mean (SEM) P P
Fasting plasma-glucose (mmol/L) 5.6 (0.1) 5.1 (0.1) 0.0041∗ 0.10
Glycated hemoglobin (HbAlc) 0.056 (0.0008) 0.054 (0.0008) 0.23 0.68
Plasma-cholesterol total (mmol/L) 5.5 (0.3) 5.1 (0.2) 0.27 0.12
Weight (kg) 76.1 (2.8) 69.2 (2.0) 0.071 0.0083∗
Body Mass Index (BMI) (kg/m 24.6 (0.7) 23.4 (0.9) 0.26 0.0069∗
Systolic blood pressure (mmHg) 151.4 (4.8) 132.4 (5.6) 0.015∗ 0.013∗
Diastolic blood pressure (mmHg) 88.8 (2.7) 80.3 (2.5) 0.035∗ 0.19
Heart rate (bpm) 68.4 (4.3) 66.1 (1.8) 0.67 0.46
Data are presented as mean (SEM), and P-value is calculated using paired/independent samples t-test. ∗P < 0.05.
and in precuneus (P = 0.055, 3.99 ml/hg/min, 95% CI: −0.10;
6.45). No significant changes occurred in liraglutide group brains
(P ≥ 0.41), or of the ratios between the two groups (P ≥ 0.13).
Cerebral Glucose Metabolism (Figure 2)
Percentage changes of CMRglc between baseline and 6-month
follow-up are shown in Figure 2A. In the placebo group, we
observed significant decreases of CMRglc by the following means
in precuneus (P = 0.009, 3.2 µmol/hg/min, 95% CI: 5.45; 0.92),
and in parietal (P = 0.04, 2.1 µmol/hg/min, 95% CI: 4.21; 0.081),
temporal (P = 0.046, 1.54 µmol/hg/min, 95% CI: 3.05; 0.030),
and occipital (P = 0.009, 2.10 µmol/hg/min, 95% CI: 3.61;
0.59) lobes, and in cerebellum (P = 0.04, 1.54 µmol/hg/min,
95% CI: 3.01; 0.064). We noted non-significant mean decreases
in the cingulate cortex (P = 0.05, 1.98 µmol/hg/min, 95% CI:
4.00; −0.042) and in cerebral cortex as a whole (P = 0.08,
−1.64 µmol/hg/min, 95% CI: 3.53; −0.25). In the GLP-1 analog
group, the CMRglc increased numerically but non-significantly
(all P ≥ 0.49) as shown in Figure 2B. In the placebo group, the
session 2/session 1 ratios of CMRglc in the cingulate (P = 0.04)
and occipital lobes (P = 0.04) declined significantly compared to
the liraglutide group.
Cognitive Outcome
We found no significant differences from baseline in total
cognitive scores after treatment within, or between, the two
groups (Table 4). Average scores at baseline were 27.1 in the
liraglutide group, and 27.2 in the placebo group (P = 0.99)
and we found no significant differences from baseline in total
cognitive score after treatment within, or between the two groups
(liraglutide 0.43, placebo 1.7; P= 0.50). A significant impairment
of the orientation test result was found in the placebo group
(P = 0.041). The scores of the liraglutide group participants did
not change.
DISCUSSION
At present, AD is treated symptomatically, and current
therapeutics target neurotransmission rather than
neurodegeneration or neuronal metabolism. This study
tested the hypothesis that treatment with the GLP-1 analog
liraglutide, a drug that potentially affects neurodegeneration,
neuronal performance, and neuroinflammation, would reduce
intracerebral Aβ deposition and improve glucose metabolism
in the CNS of patients with AD, followed by improvement
of cognition. The analog prevented the decline of brain
glucose consumption, but we found no effect on fibrillary Aβ
accumulation or cognition. The size of the cohort and the
duration of the study, however, precluded definite clinical
conclusions but the results encouraged further investigations.
[11C]PIB Retention
A conventional explanation of the pathogenesis of AD is the Aβ
cascade, according to which increased production or decreased
clearance of fibrillary Aβ leads to loss of dendritic spines and
symptoms of dementia (Hardy and Higgins, 1992). Patients
with fibrillary Aβ deposits have statistically greater retention
of [11C]PIB than patients without the Aβ deposits, and the
binding correlates with amyloid deposits in brain tissue removed
at autopsy (Leinonen et al., 2008). Here, we observed a slight
but insignificant numerical increase of the estimates of amyloid
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FIGURE 1 | (A) Percentage change in Binding Potential in the brain (BPND) between baseline scan and 6-month follow-up. (B) Binding Potential in the brain (BPND)
in the cingulate cortex, precuneus, frontal, parietal, temporal, and occipital lobes, cerebellum and cerebral cortex at baseline and the Ratio Session 2/1 in the
placebo group and the liraglutide group.∗P < 0.05.
accumulation in all cortical areas after the 6 months of treatment,
with no differences between the two groups.
In contrast, animal studies have shown significant changes
in Aβ load after treatment with the GLP-1 analog liraglutide
(McClean et al., 2011). The present patients therefore may be
at the stage of the disease at which [11C]PIB binding no longer
undergoes the increases seen in the animal models (Engler et al.,
2006; Kadir et al., 2012). A direct correlation between disease
progression and [11C]PIB retention has not been demonstrated.
As suggested by the US NIA-Alzheimer’s Association, biomarkers
of AD (hyperphosphorylated tau and Aβ) have the necessary
specificity for a diagnosis of AD, whereas tracers of brain
metabolic changes such as [18F]FDG serve to assess disease
progression and treatment effect (Dubois et al., 2014). Thus,
the finding was negative for the primary outcome, but we
cannot exclude an effect of liraglutide on Aβ accumulation to a
significant degree, such as predicted in the power calculations for
this study of patients at an earlier stage. The number analyzed
(n = 14) approached but did not reach the number obtained
by power calculation (n = 16), leading us to be cautious with
conclusions of this variable.
In three studies, Hölscher and colleagues reported that GLP-1
mimetics have prophylactic effects and reduce Alzheimer-like
disease progression in the APP/PS1 mouse model. The reduction
was most pronounced in the early stages of this animal model of
AD (McClean et al., 2015), compared to middle-aged mice with
disease advanced to a stage where the first behavioral symptoms
appear (McClean et al., 2011), and in aged APP/PS1 mice
representing the late stage of AD (McClean and Holscher, 2014).
The randomization in the present study resulted in significantly
longer duration of AD in the liraglutide treated group of patients.
The different disease durations and the short period of treatment
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FIGURE 2 | (A) Percentage change in cerebral metabolic rate for glucose (CMRglc) between baseline scan and 6-month follow-up. (B) Cerebral metabolic rate for
glucose uptake (CMRglc) in the cingulate cortex, precuneus, frontal, parietal, temporal, and occipital lobes, cerebellum, and cerebral cortex at baseline and the Ratio
Session 2/1 in the placebo group and the liraglutide group. ∗P < 0.05.
may have blunted a significant effect of the GLP-1 analog on the
disease marker at the earlier stage.
The sCBF measures gleaned from the [11C]PIB retention
increased in the placebo group, but the implications of the
increase are not clear. Recently, Lacalle-Aurioles et al. (2014)
noted an inverse relation between CBF and cortical thickness that
suggested an increase of CBF associated with cortical atrophy in
pre-dementia stages of AD. Such increases would tend to rule
out deficient oxygen or glucose delivery as explanations of the
declining metabolism of glucose (Rodell et al., 2012).
Cerebral Glucose Metabolism (CMRglc)
As a pre-specified secondary outcome, we measured CMRglc.
Reductions of CMRglc commonly are correlated with cognitive
decline in patients with AD, in particular in the parietotemporal,
frontal, and posterior cingulate cortices (Mosconi, 2005; Engler
et al., 2006; Nordberg et al., 2010), and PET with [18F]FDG
reveals the progressive reduction in cerebral glucose metabolism
in patients with subsequent pathologically proven AD before
clinical symptoms are detected (Nordberg et al., 2010).
In the precuneus and parietal, temporal, and occipital
cortices, and in cerebellum, participants treated with placebo
had significantly decreased CMRglc after 6 months, in agreement
with PET determinations of glucose metabolism in AD that
show a consistent pattern of reduced cerebral glucose utilization
beginning in parietal and temporal regions, later spreading to
prefrontal cortices (Small et al., 2000). Also, the magnitude of
CMRglc decrease is compatible with previous reports (Alexander
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TABLE 4 | Cognitive outcome.
Wechsler Memory
Scale (WMS-IV)
Placebo group (n = 20) Liraglutide group (n = 14) Change placebo vs.
change liraglutide group
Baseline After 6 months Baseline After 6 months
mean (SD) mean (SD) mean (SD) mean (SD) P
Orientation) 3.0 (3.2) 1.3 (2.2)∗ 1.9 (3.1) 2.0 (2.9) 0.085
Time estimation 1.7 (1.6) 2.0 (1.8) 1.7 (1.5) 1.2 (1.2) 0.20
Mental control 4.8 (4.9) 4.7 (4.9) 4.9 (4.6) 4.9 (4.7) 0.93
Clock drawing 2.7 (1.4) 2.7 (1.5) 2.2 (1.6) 2.6 (1.3) † 0.25
Incidental recall 2.4 (3.1)U 1.9 (3.0) 0.57 (1.2) 0.14 (0.53)‡ 0.88
Inhibition 9.9 (5.7) 10.6 (6.1) 12.4 (4.8) 11.9 (5.0) 0.10
Verbal reproduction 2.7 (2.5) 2.4 (2.5) 3.4 (2.5) 3.9 (2.4) 0.34
Total score 27.2 (17.0) 25.5 (17.0) 27.1 (12.8) 26.6 (13.0) 0.50
Tests for orientation, time estimation, mental control, clock drawing, incidental recall, inhibition, and verbal production are done using Mann–Whitney test. Total score are
done using independent samples t-test. All data presented as means ± SD. ∗Visit2 > Visit5, P = 0.041; †Visit5 > Visit2, P = 0.15; UPlacebo group > liraglutide group
for Visit 2, P = 0.064; ‡Visit5 < Visit2, P = 0.083.
et al., 2002). The [18F]FDG metabolite retention in brain is
sensitive to disease progression, and decline is closely related
to cognitive impairment (Dubois et al., 2014). In contrast,
patients treated with liraglutide had numerical but statistically
insignificant increases of CMRglc after 6 months, implying that
the GLP-1 analog treatment prevented the decline of CMRglc
that reflects cognitive impairment, synaptic dysfunction, and
disease progression, despite longer disease duration in this
group.
Little is known of the effects of GLP-1 and analogs on brain
metabolism, but the present results are in line with previously
documented effects of GLP-1 on cerebral glucose metabolism
(Gejl et al., 2012, 2013). Multiple physiological mechanisms may
explain this observation: The brain import of glucose across the
blood-brain barrier occurs by means of stereospecific and non-
energy-demanding facilitated diffusion, mediated by the glucose
transporter GLUT1 (Gjedde, 1983). The number of glucose
transporters is reduced in AD (Simpson et al., 1994; Mooradian
et al., 1997), and accelerated amyloid load and aggravated Aβ
accumulation recently were shown in a transgenic mouse model
of AD with GLUT1 deficiency (Winkler et al., 2015). Native GLP-
1 may have a direct activating effect on transport by GLUT1 in
brain capillary endothelium (Gejl et al., 2013, 2014), by which
mechanism liraglutide may be expected to prevent the decline in
glucose uptake in AD.
It is known that a decline of blood–brain barrier transport
of glucose fails directly to limit brain glucose metabolism
that is regulated by hexokinase activity (Gejl et al., 2014).
Recently, restoration of cerebral and systemic microvascular
architecture by liraglutide treatment was reported to prevent
further microvascular degeneration in AD and decline of glucose
transport (Kelly et al., 2015). Molecular links exist between
reduced insulin signaling in brain of AD patients, and peripheral
insulin signaling in patients with diabetes have both been
established (Bomfim et al., 2012), and liraglutide has been
reported to prevent this insulin desensitization in the brain
and to reverse insulin signaling impairments in human AD
brain tissue (Talbot et al., 2011). As demonstrated by Craft
et al. (2012), insulin administered intranasally raises CMRglc in
AD. Therefore, the activation by liraglutide of insulin-related
pathways is a possible explanation of the results (Freiherr et al.,
2013).
Diminished glucose metabolism characterizes AD and
correlates with impaired cognition (Hunt et al., 2007). The
advanced stage of AD in this study along with the uneven
randomization regarding disease duration may have led to an
underestimation of the effects of treatment. Future clinical trials
focusing on patients with mild cognitive impairment may prove
more effective in specifically delineating the glucose-related
effects of liraglutide on cognition.
Cognition
Animal studies suggest that cognition may be improved by
liraglutide (Hansen et al., 2015). In the present study, cognitive
testing revealed no significant decrease of WMS score in either
group after 6 months of treatment with liraglutide versus placebo,
although negative changes of cognition over time seemed smaller
in the liraglutide-treated group. A significant impairment in the
orientation test was found in the placebo group and not in
the liraglutide group, but the study was underpowered for this
outcome. Thus, the cognitive assessment was not definitive.
Side Effects
The risk of hypoglycaemia is very low for liraglutide as its
effects on insulin secretion are glucose dependent. No subject
experienced side effects related to hypoglycaemia and HbA1c
levels were unaffected.
The most common side effects reported in patients treated
with liraglutide are gastrointestinal, mostly transient nausea, as
also observed here. As expected, most cases of nausea occurred
during the first 4 weeks. One dropout in the liraglutide group was
due to side effects.
Moderate weight loss has been reported in diabetes patients
treated with liraglutide. A significant weight loss was seen in
the liraglutide group. The weight loss abated after 2–3 months
of treatment. The weight reduction with GLP-1 agonists
is predominantly due to a reduction in adipose tissue,
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especially visceral adipose tissue, rather than to a reduction in
muscle mass (Jendle et al., 2009). Weight loss, the main side
effect, must be evaluated closely in future studies, however.
Whether liraglutide-induced changes in weight or BMI can
be linked to cerebral glucose metabolism or other outcome
variable of the patients remains to be determined, as a clear link
between cerebral and peripheral insulin resistance has yet to be
established.
We found a significant decrease in systolic blood pressure after
6 months of GLP-1 analog treatment, compared to the placebo
group. We found no change in heart rate at the end of the study
period in either group.
CONCLUSION
In AD patients with long-standing disease, 26 weeks of liraglutide
treatment prevented the expected decline of CMRglc that reflects
disease progression, as observed in the placebo group. We found
no differences between the groups treated with liraglutide and
placebo with respect to amyloid deposition or cognition.
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